Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PHENETRON.
CLARINEX-D 12 HOUR vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine